色素-话题@MedSci

#色素#

654篇内容 | 6189人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1680753, encodeId=e3181680e531c, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Eur J Cancer：阿西替尼联合抗PD-1抗体治疗晚期黏膜黑色素瘤的实际疗效和安全性, objectType=article, longId=216279, objectId=b8872162e982, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8872162e982, replyNumber=0, likeNumber=116, createdTime=2022-02-12, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8872162e982, moduleTitle=Eur J Cancer：阿西替尼联合抗PD-1抗体治疗晚期黏膜黑色素瘤的实际疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8872162e982)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680752, encodeId=81e21680e52cb, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=一文读懂：黑色素瘤的全新治疗进展, objectType=article, longId=216087, objectId=eb1221608e10, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb1221608e10, replyNumber=0, likeNumber=53, createdTime=2021-12-24, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb1221608e10, moduleTitle=一文读懂：黑色素瘤的全新治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb1221608e10)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680735, encodeId=91411680e357a, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Hepatol Int:晚期黑色素瘤患者中免疫检查点抑制剂介导的肝炎与肝转移和临床预后的关系, objectType=article, longId=213469, objectId=74a52134694c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74a52134694c, replyNumber=0, likeNumber=68, createdTime=2021-12-25, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74a52134694c, moduleTitle=Hepatol Int:晚期黑色素瘤患者中免疫检查点抑制剂介导的肝炎与肝转移和临床预后的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74a52134694c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680756, encodeId=45b31680e56b1, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Clin Cancer Res：Ceralasertib(AZD6738)联合紫杉醇或可有效治疗PD1/L1耐药性黑色素瘤, objectType=article, longId=216637, objectId=99fe21663e10, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99fe21663e10, replyNumber=0, likeNumber=142, createdTime=2021-12-19, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99fe21663e10, moduleTitle=Clin Cancer Res：Ceralasertib(AZD6738)联合紫杉醇或可有效治疗PD1/L1耐药性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99fe21663e10)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680724, encodeId=6a241680e240d, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Lancet Oncol：伊匹单抗联合抗PD-1疗法显著改善了对抗PD-1耐药的晚期黑色素瘤患者的临床预后, objectType=article, longId=211183, objectId=ec8c211183ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec8c211183ba, replyNumber=0, likeNumber=70, createdTime=2021-09-29, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec8c211183ba, moduleTitle=Lancet Oncol：伊匹单抗联合抗PD-1疗法显著改善了对抗PD-1耐药的晚期黑色素瘤患者的临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec8c211183ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680730, encodeId=deb21680e30e7, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Br J Cancer：体育活动、握力和久坐行为与恶性黑色素瘤发病风险之间的相关性研究, objectType=article, longId=212167, objectId=696921216e5e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=696921216e5e, replyNumber=0, likeNumber=72, createdTime=2022-03-31, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=696921216e5e, moduleTitle=Br J Cancer：体育活动、握力和久坐行为与恶性黑色素瘤发病风险之间的相关性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=696921216e5e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680738, encodeId=da0a1680e38d6, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Clin Cancer Res：标准剂量Pembrolizumab 联合不同剂量Ipilimumab治疗晚期黑色素瘤的疗效：KEYNOTE-029 队列1C。, objectType=article, longId=213761, objectId=ae12213e61f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae12213e61f4, replyNumber=0, likeNumber=124, createdTime=2021-07-11, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae12213e61f4, moduleTitle=Clin Cancer Res：标准剂量Pembrolizumab 联合不同剂量Ipilimumab治疗晚期黑色素瘤的疗效：KEYNOTE-029 队列1C。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae12213e61f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680754, encodeId=f8ac1680e54f3, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=J Clin Oncol：溶瘤柯萨奇病毒A21(V937)治疗不可切除的黑色素瘤的临床反应和安全性, objectType=article, longId=216578, objectId=b7f12165e835, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7f12165e835, replyNumber=0, likeNumber=85, createdTime=2021-09-24, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7f12165e835, moduleTitle=J Clin Oncol：溶瘤柯萨奇病毒A21(V937)治疗不可切除的黑色素瘤的临床反应和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7f12165e835)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680742, encodeId=e8bb1680e4225, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Br J Cancer：免疫检查点抑制剂ICI预治疗提高达卡巴嗪治疗转移性黑色素瘤的疗效, objectType=article, longId=214405, objectId=fc05214405fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc05214405fd, replyNumber=0, likeNumber=68, createdTime=2022-02-13, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc05214405fd, moduleTitle=Br J Cancer：免疫检查点抑制剂ICI预治疗提高达卡巴嗪治疗转移性黑色素瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc05214405fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680726, encodeId=cae51680e26aa, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Nat Commun：出乎意料，紫外线可以抑制黑色素瘤侵袭 , objectType=article, longId=211392, objectId=fd4321139291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd4321139291, replyNumber=0, likeNumber=93, createdTime=2021-10-09, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd4321139291, moduleTitle=Nat Commun：出乎意料，紫外线可以抑制黑色素瘤侵袭 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd4321139291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680700, encodeId=2a931680e004a, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Eur J Cancer：鉴别高复发风险的I/IIA期黑色素瘤的新模型, objectType=article, longId=203757, objectId=8707203e5749, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8707203e5749, replyNumber=0, likeNumber=77, createdTime=2020-12-24, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8707203e5749, moduleTitle=Eur J Cancer：鉴别高复发风险的I/IIA期黑色素瘤的新模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8707203e5749)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680701, encodeId=957e1680e0132, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Cell Death Differ：Fra-2/AP-1下调Fam212b表达调节黑色素瘤细胞的转移, objectType=article, longId=203815, objectId=1a1020381523, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a1020381523, replyNumber=0, likeNumber=73, createdTime=2021-06-28, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a1020381523, moduleTitle=Cell Death Differ：Fra-2/AP-1下调Fam212b表达调节黑色素瘤细胞的转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a1020381523)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680708, encodeId=e1511680e0816, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Cell Death Differ：FBXO32：关联黑色素瘤细胞中泛素化作用与表观遗传重塑的关键因子, objectType=article, longId=206039, objectId=38992060392e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38992060392e, replyNumber=0, likeNumber=68, createdTime=2021-08-17, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38992060392e, moduleTitle=Cell Death Differ：FBXO32：关联黑色素瘤细胞中泛素化作用与表观遗传重塑的关键因子, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38992060392e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680722, encodeId=9b3d1680e22d2, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Br J Cancer：免疫检查点阻断治疗诱导的自身免疫与转移性黑色素瘤的预后和独特的T细胞表达谱相关, objectType=article, longId=208869, objectId=3c442088690f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c442088690f, replyNumber=0, likeNumber=60, createdTime=2021-07-07, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c442088690f, moduleTitle=Br J Cancer：免疫检查点阻断治疗诱导的自身免疫与转移性黑色素瘤的预后和独特的T细胞表达谱相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c442088690f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680732, encodeId=8ed71680e321c, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Nat Commun：紫外线照射诱导胶原蛋白的降解并抑制黑色素瘤的侵袭作用, objectType=article, longId=212649, objectId=729e2126490f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=729e2126490f, replyNumber=0, likeNumber=93, createdTime=2022-04-05, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=729e2126490f, moduleTitle=Nat Commun：紫外线照射诱导胶原蛋白的降解并抑制黑色素瘤的侵袭作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=729e2126490f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680687, encodeId=a84c168068ec6, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Clin Cancer Res：靶向细胞外基质重构可恢复BRAFi耐药性黑色素瘤对BRAF抑制剂的敏感性, objectType=article, longId=200028, objectId=1381200028b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1381200028b8, replyNumber=0, likeNumber=71, createdTime=2020-09-26, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1381200028b8, moduleTitle=Clin Cancer Res：靶向细胞外基质重构可恢复BRAFi耐药性黑色素瘤对BRAF抑制剂的敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1381200028b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680706, encodeId=9c6f1680e0607, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=TAVO联合OPDIVO作为黑色素瘤的新型辅助疗法：II期试验中患者首次给药, objectType=article, longId=205631, objectId=e7872056314a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7872056314a, replyNumber=0, likeNumber=75, createdTime=2021-02-19, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7872056314a, moduleTitle=TAVO联合OPDIVO作为黑色素瘤的新型辅助疗法：II期试验中患者首次给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7872056314a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680688, encodeId=0f1f16806885d, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人, objectType=article, longId=200218, objectId=b6bb200218dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6bb200218dc, replyNumber=0, likeNumber=86, createdTime=2021-03-14, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6bb200218dc, moduleTitle=NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6bb200218dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680689, encodeId=cb4a1680689d9, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=PD1+溶瘤病毒，奥源和力公布OrienX010一项黑色素瘤Ib期研究结果, objectType=article, longId=201030, objectId=51052010304a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51052010304a, replyNumber=0, likeNumber=73, createdTime=2021-05-17, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51052010304a, moduleTitle=PD1+溶瘤病毒，奥源和力公布OrienX010一项黑色素瘤Ib期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51052010304a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680731, encodeId=de171680e3196, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=SCIENCE：粪便微生物群移植可能有助于消除黑色素瘤患者对免疫治疗的耐药性, objectType=article, longId=212522, objectId=1f72212522ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f72212522ed, replyNumber=0, likeNumber=90, createdTime=2022-03-06, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f72212522ed, moduleTitle=SCIENCE：粪便微生物群移植可能有助于消除黑色素瘤患者对免疫治疗的耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f72212522ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

色素

2020-05-29

sunylz (审核中...)

前往app查看评论内容

#色素#

Eur J Cancer：阿西替尼联合抗PD-1抗体治疗晚期黏膜黑色素瘤的实际疗效和安全性

2022-02-12

sunylz (审核中...)

前往app查看评论内容

#色素#

一文读懂：黑色素瘤的全新治疗进展

2021-12-24

sunylz (审核中...)

前往app查看评论内容

#色素#

Hepatol Int:晚期黑色素瘤患者中免疫检查点抑制剂介导的肝炎与肝转移和临床预后的关系

2021-12-25

sunylz (审核中...)

前往app查看评论内容

#色素#

Clin Cancer Res：Ceralasertib(AZD6738)联合紫杉醇或可有效治疗PD1/L1耐药性黑色素瘤

2021-12-19

sunylz (审核中...)

前往app查看评论内容

#色素#

Lancet Oncol：伊匹单抗联合抗PD-1疗法显著改善了对抗PD-1耐药的晚期黑色素瘤患者的临床预后

2021-09-29

sunylz (审核中...)

前往app查看评论内容

#色素#

Br J Cancer：体育活动、握力和久坐行为与恶性黑色素瘤发病风险之间的相关性研究

2022-03-31

sunylz (审核中...)

前往app查看评论内容

#色素#

Clin Cancer Res：标准剂量Pembrolizumab 联合不同剂量Ipilimumab治疗晚期黑色素瘤的疗效：KEYNOTE-029 队列1C。

2021-07-11

sunylz (审核中...)

前往app查看评论内容

#色素#

J Clin Oncol：溶瘤柯萨奇病毒A21(V937)治疗不可切除的黑色素瘤的临床反应和安全性

2021-09-24

sunylz (审核中...)

前往app查看评论内容

#色素#

Br J Cancer：免疫检查点抑制剂ICI预治疗提高达卡巴嗪治疗转移性黑色素瘤的疗效

2022-02-13

sunylz (审核中...)

前往app查看评论内容

#色素#

Nat Commun：出乎意料，紫外线可以抑制黑色素瘤侵袭

2021-10-09

sunylz (审核中...)

前往app查看评论内容

#色素#

Eur J Cancer：鉴别高复发风险的I/IIA期黑色素瘤的新模型

2020-12-24

sunylz (审核中...)

前往app查看评论内容

#色素#

Cell Death Differ：Fra-2/AP-1下调Fam212b表达调节黑色素瘤细胞的转移

2021-06-28

sunylz (审核中...)

前往app查看评论内容

#色素#

Cell Death Differ：FBXO32：关联黑色素瘤细胞中泛素化作用与表观遗传重塑的关键因子

2021-08-17

sunylz (审核中...)

前往app查看评论内容

#色素#

Br J Cancer：免疫检查点阻断治疗诱导的自身免疫与转移性黑色素瘤的预后和独特的T细胞表达谱相关

2021-07-07

sunylz (审核中...)

前往app查看评论内容

#色素#

Nat Commun：紫外线照射诱导胶原蛋白的降解并抑制黑色素瘤的侵袭作用

2022-04-05

sunylz (审核中...)

前往app查看评论内容

#色素#

Clin Cancer Res：靶向细胞外基质重构可恢复BRAFi耐药性黑色素瘤对BRAF抑制剂的敏感性

2020-09-26

sunylz (审核中...)

前往app查看评论内容

#色素#

TAVO联合OPDIVO作为黑色素瘤的新型辅助疗法：II期试验中患者首次给药

2021-02-19

sunylz (审核中...)

前往app查看评论内容

#色素#

NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人

2021-03-14

sunylz (审核中...)

前往app查看评论内容

#色素#

PD1+溶瘤病毒，奥源和力公布OrienX010一项黑色素瘤Ib期研究结果

2021-05-17

sunylz (审核中...)

前往app查看评论内容

#色素#

SCIENCE：粪便微生物群移植可能有助于消除黑色素瘤患者对免疫治疗的耐药性

2022-03-06

科室
- - 订阅+
  - 更多科室
工具
服务